Prognostic factors for patients with small cell lung carcinoma: Analysis of a series of 763 patients included in 4 consecutive prospective trials with a minimum follow-up of 5 years

Cancer

Volumn 89, Issue 3, 2000, Pages 523-533

  Paesmans, M ^a   Sculier, J P ^a   Lecomte, J ^b   Thiriaux, J ^b   Libert, P ^c   Sergysels, R ^d   Bureau, G ^e   Dabouis, G ^f   Van Cutsem, O ^g   Mommen, P ^a   Ninane, V ^d   Klastersky, J ^a  

^a JULES BORDET INSTITUTE   (Belgium)

^b Hospital Civil Charleroi   (Belgium)

^c Hôpital de Warquignies   (Belgium)

^d SAINT PIERRE UNIVERSITY HOSPITAL   (Belgium)

^e Groupe Médical St Rémi   (France)

^f NANTES UNIVERSITY HOSPITAL   (France)

^g Clinique St Luc Bouge   (Belgium)

Author keywords

Cure; Long term survival; Prognostic factors; Response to chemotherapy; Small cell lung carcinoma; Survival

Indexed keywords

CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; IFOSFAMIDE; METHOTREXATE; VINCRISTINE; VINDESINE;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; FEMALE; FOLLOW UP; HUMAN; LEUKOCYTE COUNT; LUNG SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; SURVIVAL TIME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SMALL CELL; CLINICAL TRIALS; FEMALE; FOLLOW-UP STUDIES; HUMANS; LOGISTIC MODELS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; SURVIVAL ANALYSIS;

EID: 0034255522     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/1097-0142(20000801)89:3<523::AID-CNCR7>3.0.CO;2-6     Document Type: Article

References (49)

1. Cancer statistics, 1994
2. Chemotherapy of lung cancer
3. Determinants of improved outcome in small-cell lung cancer: An analysis of the 2,580-patient Southwest Oncology Group data base
4. Phase II study of an intensive combination chemotherapy with cisplatin, adriamycin, etoposide and cyclophosphamide (CAVE) in small cell lung cancer
5. A randomized study comparing etoposide and vindesine with or without cisplatin as induction therapy for small cell lung cancer. EORTC Lung Cancer Working Party
6. Multiple-drug weekly chemotherapy versus standard combination regimen in small-cell lung cancer: A phase III randomized study conducted by the European Lung Cancer Working Party
7. Randomized trial comparing induction chemotherapy versus induction chemotherapy followed by maintenance chemotherapy in small-cell lung cancer. European Lung Cancer Working Party
8. Regression and recursive partition strategies in the analysis of medical survival data
9. Prognostic factors for survival in advanced non-small-cell lung cancer: Univariate and multivariate analyses including recursive partitioning and amalgamation algorithms in 1,052 patients. The European Lung Cancer Working Party
10. Improvement and plateau in survival of small-cell lung cancer since 1975: A population-based study
11. Small cell carcinoma of the lung. A progress report of 15 years' experience
12. Long-term survival in small-cell carcinoma of the lung: A population experience
13. Ten-year survival of patients with small-cell lung cancer treated with combination chemotherapy with or without irradiation
14. Long-term survival in small cell carcinoma of the lung
15. Long-term disease-free survival in small-cell carcinoma of the lung: A study of clinical determinants
16. Survival determinants in extensive-stage non-small-cell lung cancer: The Southwest Oncology Group experience
17. Long-term survival in small cell lung cancer: The case for a standard definition. Medical Research Council Lung Cancer Working Party
18. Outcome of patients with small-cell lung cancer during 20 years of clinical research at the US National Cancer Institute
19. A meta-analysis of thoracic radiotherapy for small-cell lung cancer [see comments]
20. Does thoracic irradiation improve survival and local control in limited-stage small-cell carcinoma of the lung? A meta-analysis
21. Revue critique des etudes randomisees evaluant le role de la radiotherapie thoracique adjuvante a la chimiotherapie dans le traitement du cancer bronchique a petites cellules au stade limite
22. Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide
23. Long-term survival in small cell lung cancer: The case for a standard definition. Medical Research Council Lung Cancer Working Party
24. Importance of prognostic factors in cancer clinical trials
25. Small-cell lung cancer: Patients included in clinical trials are not representative of the patient population as a whole
26. Determinants of complete remission induction and maintenance in chemotherapy with or without irradiation of small cell lung cancer
27. Normal serum neuron specific enolase (NSE) value after the first cycle of chemotherapy: An early predictor of complete response and survival in patients with small cell lung carcinoma
28. Prognostic factors in small cell lung cancer: Multivariate model based on 778 patients treated with chemotherapy with or without irradiation
29. Prognostic factors in small-cell carcinoma of the lung: An analysis of 1,521 patients
30. Small-cell carcinoma of the lung: Derivation of a prognostic staging system
31. Analysis of prognostic factors in 766 patients with small cell lung cancer (SCLC): The role of sex as a predictor for survival
32. Serum neuron-specific enolase (SNSE) and the prognosis in small-cell lung cancer (SCLC): A combined multivariable analysis on data from nine centres
33. The Will Rogers phenomenon. Stage migration and new diagnostic techniques as a source of misleading statistics for survival in cancer
34. Outcome of patients with small-cell lung cancer: Effect of changes in staging procedures and imaging technology on prognostic factors over 14 years
35. Prognosis at presentation of small cell carcinoma of the lung
36. A randomised trial of three or six courses of etoposide cyclophosphamide methotrexate and vincristine or six courses of etoposide and ifosfamide in small cell lung cancer (SCLC) I: Survival and prognostic factors. Medical Research Council Lung Cancer Working Party
37. Pretreatment minimal staging and prognostic factors for non-small cell lung cancer
38. Pretreatment prognostic factors and scoring system in 407 small-cell lung cancer patients
39. Prognostic factors and prognostic staging system for small cell lung cancer
40. Long-term survival after chemotherapy containing platinum derivatives in patients with advanced unresectable non-small cell lung cancer. European Lung Cancer Working Party
41. Long-term survival in small-cell lung cancer: Posttreatment characteristics in patients surviving 5 to 18± years - An analysis of 1,714 consecutive patients
42. Long-term disease-free survival in small-cell carcinoma of the lung: A study of clinical determinants
43. Chimiotherapie des cancers bronchiques a petites cellules. Impotance d'une reponse complete. (1,280 patients). Groupe Petites Cellules
44. Long-term survivors of small-cell lung cancer (SCLC): A French multicenter study
45. Statistical aspects of prognostic factor studies in oncology [editorial]